Baxter‘s (NYSE:BAX) said today it inked a licensing agreement with Tel Aviv University’s Ramot business engagement center through which the company aims to bring early stage research technologies in development at the university to the market.
As part of the agreement, Baxter said it will gain an exclusive license for the TAU Technology Innovation Momentum Fund tech in 1 license agreement and TAU and Tel Aviv Sourasky Medical Center tech in a 2nd.
“Baxter is committed to finding creative pathways to bring innovative solutions to the operating room. By working with leading experts at TAU and TASMC, we have access to promising early-stage research that could have a meaningful impact for surgeons looking for new tools to treat complex cases,” Baxter advanced surgery prez Wil Boren said in a press release.
Baxter said that it and its partners plan to explore potential applications for multiple projects targeting large unmet needs.
“TAU is world renowned as a leading academic and research institution for its innovation and entrepreneurship. We are gratified to see another one of TAU’s technologies graduating from our unique value enhancement program the TAU Technology Innovation Momentum Fund. We are happy to partner with Baxter to explore how we can bring leading technologies to operating rooms worldwide,” Ramot CEO Shlomo Nimrodi said in a prepared statement.
In June, Baxter released data from multiple studies of its Sharesource remote patient monitoring technology used for peritoneal dialysis patient care.